Immunomedics' yttrium-90-labeled hPAM4, a treatment for pancreatic cancer, obtained fast-track designation from the FDA. The drug is undergoing early-stage clinical development.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||